VOLTAREN Drug Patent Profile

Which patents cover Voltaren, and what generic alternatives are available?

Voltaren is a drug marketed by Novartis and Haleon Us Holdings and is included in four NDAs.

The generic ingredient in VOLTAREN is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Voltaren

A generic version of VOLTAREN was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26^th, 1996.

Summary for VOLTAREN

US Patents:	0
Applicants:	2
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	59
Patent Applications:	7,090
Drug Prices:	Drug price information for VOLTAREN
Drug Sales Revenues:	Drug sales revenues for VOLTAREN
What excipients (inactive ingredients) are in VOLTAREN?	VOLTAREN excipients list
DailyMed Link:	VOLTAREN at DailyMed

See drug prices for VOLTAREN

See drug sales revenues for VOLTAREN

Recent Clinical Trials for VOLTAREN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mariam Hesham Mahmoud Abdelfattah Eissa	NA
HALEON	NA
HALEON	PHASE4

See all VOLTAREN clinical trials

Pharmacology for VOLTAREN

Drug Class	Anti-coagulant Calculi Dissolution Agent
Mechanism of Action	Acidifying Activity Calcium Chelating Activity
Physiological Effect	Decreased Coagulation Factor Activity

US Patents and Regulatory Information for VOLTAREN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VOLTAREN	diclofenac sodium	SOLUTION/DROPS;OPHTHALMIC	020037-001	Mar 28, 1991		DISCN	Yes	No
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-003	Jul 28, 1988		DISCN	Yes	No
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-001	Jul 28, 1988		DISCN	Yes	No
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-002	Jul 28, 1988		DISCN	Yes	No
Novartis	VOLTAREN-XR	diclofenac sodium	TABLET, EXTENDED RELEASE;ORAL	020254-001	Mar 8, 1996		DISCN	Yes	No
Haleon Us Holdings	VOLTAREN ARTHRITIS PAIN	diclofenac sodium	GEL;TOPICAL	022122-001	Oct 17, 2007		OTC	Yes	Yes

Expired US Patents for VOLTAREN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	VOLTAREN	diclofenac sodium	SOLUTION/DROPS;OPHTHALMIC	020037-001	Mar 28, 1991	4,960,799
Novartis	VOLTAREN	diclofenac sodium	SOLUTION/DROPS;OPHTHALMIC	020037-001	Mar 28, 1991	3,652,762
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-003	Jul 28, 1988	3,652,762
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-001	Jul 28, 1988	3,652,762
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-002	Jul 28, 1988	3,652,762
Novartis	VOLTAREN	diclofenac sodium	SOLUTION/DROPS;OPHTHALMIC	020037-001	Mar 28, 1991	4,829,088

International Patents for VOLTAREN

See the table below for patents covering VOLTAREN around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	13194
South Africa	8702624
Japan	2515788
Norway	174916
Denmark	176487
Norway	871549
Canada	1286225	MEDICAMENT POUR LE TRAITEMENT DES INFLAMMATIONS DE L'OEIL (MEDICAMENT FOR THE TREATMENT OF INFLAMMATIONS OF THE EYE)

VOLTAREN (diclofenac) Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What does VOLTAREN earn from across markets and dosage forms?

VOLTAREN is a global brand for diclofenac, used in oral (where approved), topical (notably gel), and other formulations depending on country. Financial performance is dispersed across geographies and product types because ownership and manufacturing rights differ by territory, and because diclofenac is off-patent in many markets. As a result, VOLTAREN’s revenue trajectory is dominated by (1) generic price levels, (2) category demand for pain management, and (3) ongoing regulatory and access constraints that shape prescribing and reimbursement.

Core implication for investors and R&D planners: VOLTAREN behaves less like a single “patent asset” and more like a mature consumer-and-prescriber brand in an off-patent NSAID class, where share gains come from packaging, channel execution, and local approvals rather than exclusivity.

---

How has regulation reshaped the diclofenac category?

Diclofenac’s market path has been materially affected by safety signals tied to cardiovascular and gastrointestinal risk and by subsequent regulatory actions that vary by jurisdiction. The strictness and enforcement intensity affects both prescribing and product positioning within NSAID alternatives.

Key regulatory effects that influence sales trajectories:

• Label narrowing and warnings in multiple markets reduced the eligible patient population and shifted prescribers toward alternatives depending on local risk-benefit framing.
• Restrictive usage guidance reduced long-duration or higher-risk use cases.
• Topical versus oral substitution increased in markets where topical diclofenac retained a better risk profile than systemic NSAIDs for certain indications.

This regulatory mix tends to support the topical brand franchise while pressuring oral or higher-dose segments, depending on local rules.

---

What are the main market drivers and competitive pressures?

VOLTAREN’s demand drivers

• Persistent incidence of musculoskeletal pain, osteoarthritis, and sports-related minor injuries.
• Consumer acceptance of topical NSAIDs, especially for localized pain where patients prefer non-prescription self-care where allowed.

Competitive pressures

• Generic diclofenac at significant price discounts in most off-patent settings.
• Other topical NSAIDs (and competing non-NSAID topical pain products) that fight for pharmacy shelf space and formulary preference.
• Non-pharmaceutical channels: patient switching to other over-the-counter analgesics where pricing and brand awareness shift.

Market structure reality: In mature NSAID categories, brand share is heavily influenced by retail promotion cadence and channel access rather than clinical differentiation, because active ingredients are widely replicated.

---

How do formulation and route of administration affect financial trajectory?

VOLTAREN value creation splits into distinct economic segments:

1. Topical diclofenac (notably gel)

   • Stronger resilience because safety messaging for localized pain supports use.
   • Brand equity concentrates in topical formats where consumers can identify efficacy by results from prior use.

2. Oral diclofenac

   • More exposed to generic substitution and prescriber risk management.
   • More likely to face tighter conditions, which can cap volume growth.

3. Other formulations

   • Market size depends on national approvals and competitive intensity among locally branded products.

Financial pattern expected in practice: growth tends to track topical share retention and incremental price stabilization, while oral volume growth is more likely to be flat to declining in mature geographies.

---

What does the post-patent environment imply for revenue growth?

For off-patent molecules, revenue growth typically becomes a function of:

• Price realization vs. competitive discounting (generics compress revenue per unit)
• Mix shift toward branded premium formats (topical, larger packs, higher-strength SKUs where available)
• Geographic expansion into markets with slower generic penetration or where brand has entrenched OTC or Rx presence

When generic penetration rises, branded manufacturers often respond with:

• SKU rationalization and pack-size strategies
• Pharmacy and e-commerce promotion
• Distribution and formulation packaging that protects shelf visibility

---

How do channel dynamics move VOLTAREN results?

Retail pharmacy and OTC

• Brand awareness and promotion drive conversion.
• E-commerce can increase price transparency, which typically increases generic share unless brand runs targeted pricing and bundles.

Hospital and outpatient procurement (where applicable)

• Formulary decisions dominate.
• Safety framing and comparative value against alternative NSAIDs can shift use.

Tender and bulk contracting

• Creates volatility where public procurement concentrates on lowest net price.
• Brands can retain advantage only where they offer consistent supply, specific strengths, or contracted rebates.

---

What is the likely financial trajectory shape (base case)?

In a mature NSAID franchise, the trajectory typically follows:

• Stabilization after major regulatory shifts as products re-anchor in safer segments (often topical)
• Gradual volume erosion in jurisdictions with aggressive generic entry
• Revenue stabilization if the brand maintains mix and pricing through premium formats and retention of higher-margin SKUs
• Segmental divergence across geographies depending on reimbursement and competitive intensity

For VOLTAREN specifically, the most bankable revenue continuity is tied to its ability to defend topical branded share against multiple generic and alternative topical NSAIDs.

---

How do key corporate and licensing realities affect financial outcomes?

VOLTAREN is marketed globally under a brand framework that can differ by territory and ownership/licensing arrangements. Those structures shift who books sales and at what margin. They also determine:

• investment pace in local advertising and medical education
• the strength of pharmacy relationships
• distribution strategy for gel SKUs and pack formats
• responsiveness to competitive discounting

Business outcome: even with stable demand, reported growth rates can vary because commercial arrangements differ by market.

---

Does VOLTAREN face major supply or manufacturing risks?

In mature branded NSAIDs, supply risk usually stems from:

• site-level capacity constraints and raw material cost movements
• regulatory batch release constraints
• line changes tied to reformulation or packaging updates

These factors can cause short-term distribution disruptions but rarely produce multi-year category-level declines unless compounded by regulatory or litigation events.

---

What should analysts track to forecast VOLTAREN performance?

Forecasting requires category KPIs that map to the economic levers above:

Market-share and mix

• Topical diclofenac share vs. other topical NSAIDs
• Branded vs. generic penetration by channel
• Pack-size mix and strength mix (where available)

Pricing and promotion

• Net price vs. list price (including rebates and trade spend)
• Promo frequency and depth in pharmacy chains and e-commerce
• Private label and generic undercut rates

Regulatory and access

• Label changes and warning updates that affect eligible use
• OTC vs. Rx migration driven by local policy
• Reimbursement restrictions or formulary updates

Demand indicators

• Category growth from musculoskeletal pain incidence and aging demographics
• Seasonal peaks in injury-related localized pain usage
• Patient switching patterns among NSAIDs and alternative analgesics

---

What are the most material risks to the financial trajectory?

1. Generic price compression
   • Erodes branded revenue per unit unless mix and price realization offset it.
2. Regulatory tightening
   • Can constrain eligible indications or increase required risk controls.
3. Competitive substitution within topical pain
   • Alternative topical NSAIDs and analgesic formats can displace share.
4. Channel price transparency
   • E-commerce and couponing amplify promotional discounting races.

---

Key Takeaways

• VOLTAREN’s financial trajectory is maturity-driven: it tracks topical and channel share defense, net pricing, and generic intensity rather than patent exclusivity.
• Regulation shapes segment mix: topical diclofenac tends to hold up better than systemic use when restrictions tighten.
• Forecasts should focus on net price, branded vs. generic penetration, and mix (SKU strength and pack size) because those variables determine revenue even when unit demand is stable.
• The dominant risk is sustained generic discounting paired with active competition from other topical pain products and NSAIDs.

---

FAQs

1) Is VOLTAREN still protected by patents in major markets?

VOLTAREN’s diclofenac active ingredient is off-patent in many jurisdictions, so the brand competes primarily against generics. Market outcomes depend on branded mix, pricing, and channel execution.

2) Why does topical VOLTAREN tend to be more resilient than oral diclofenac?

Topical use often benefits from localized risk framing compared with systemic NSAID exposure, which can preserve access and consumer adoption even as systemic NSAID restrictions persist.

3) What matters most for forecasting VOLTAREN revenue?

Net price realization, branded versus generic penetration by channel, and mix shifts into higher-value topical formats (strength and pack sizes) matter more than gross demand alone.

4) How does the competitive landscape influence financial performance?

Generic diclofenac sets the floor on price, while other topical NSAIDs compete directly for pharmacy and consumer attention, shifting share and promotion intensity.

5) Which regulatory actions most affect market dynamics?

Label restrictions, warning updates, and controls tied to cardiovascular and gastrointestinal risk change eligible use patterns and can redirect category preference toward topical or alternative agents.

---

References

[1] European Medicines Agency. Diclofenac: information on risk and recommendations. (EMA website).
[2] U.S. Food and Drug Administration. Diclofenac-containing products: prescribing information and safety labeling updates. (FDA website).
[3] World Health Organization. NSAIDs and adverse event risk communications (general safety context). (WHO website).